Contineum Therapeutics, Inc. 4

CEO and President Carmine N. Stengone exercised 2,500 stock options and sold 2,500 shares of Contineum Therapeutics Class A Common Stock on 2026-08-03 under a 10b5-1 plan.

On August 3, 2026, Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., exercised stock options for 2,500 shares of Class A Common Stock at an exercise price of $1.01 per share and immediately sold the same 2,500 shares at a weighted average price of $16.0116 per share under a Rule 10b5-1 trading plan adopted on September 23, 2025. The option exercise (coded 'M') and corresponding sale (coded 'S') were executed as part of routine equity compensation activity under the issuer’s 2012 Equity Incentive Plan, with the option reported as fully vested. Following these transactions, Stengone’s direct ownership stood at 17,217 shares of Class A Common Stock, while 2,500 options at a $1.01 strike price remained outstanding and unexercised until their February 24, 2030 expiration. Based on the reported sale price, the gross value of the sale was approximately $40,029, and the market value of his remaining direct share holdings is estimated at about $276,930.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

4

Source Type

fda

Accession

0001628280-26-052031

Alert Tier

5